Yu, E. Y., Song, Y., Garratt, C., Poehlein, C. H., Schloss, C., Antonarakis, E. S. (2025). OMAHA-003: A phase 3 study of CYP11A1 inhibitor opevesostat versus next-generation hormonal agent (NHA) switch in metastatic castration-resistant prostate cancer (mCRPC) after NHA and taxane-based chemotherapy.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.tps286